On June 18, 2024, Allarity Therapeutics, Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has not complied with the Nasdaq Listing Rule 5550(a)(2) which is the requirement that for 30 consecutive business days the bid price for the Company's common stock close above the $1 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.
The Company intends to request a hearing before a Nasdaq Hearings Panel (the "Panel") at which it will request continued listing pending its return to compliance. The Company's hearing request will stay the suspension of trading and delisting of the Company's common stock pending the conclusion of the hearing process. Consequently, the Company expects its common stock to remain listed on the Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel will grant the Company's request for a suspension of delisting or continued listing on the Nasdaq Capital Market.
2024年6月18日、Allarity Therapeutics社はNasdaq Stock Market LLCのNasdaq Listing Qualifications Staffから、同社の一般株式の買気配が30営業日以上$1の最低買付価格要件を満たさなかったことを示す書簡を受け取りました。これはNasdaq Listing Rule 5550(a)(2)に違反しています。
同社はNasdaq Hearings Panelに対し、継続的な遵守を要求するヒアリングを要求する意向です。同社のヒアリングリクエストにより、一般株式の取引停止及び上場廃止が保留され、ヒアリングプロセスが終了するまで引き続きNasdaq Capital Marketに上場されることが期待されます。しかし、同社の上場廃止保留要求がNasdaq Hearings Panelから許可されるかどうかは保証されません。
ブラウザの共有ボタンを使って、このページを友人と共有することができます。
